Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Updated . What changed?
Taysha Gene Therapies, Inc is a biotechnology business based in the US. Taysha Gene Therapies shares (TSHA) are listed on the NASDAQ and all prices are listed in US Dollars.
|52-week range||USD$18.16 - USD$33.35|
|50-day moving average||USD$28.9985|
|200-day moving average||USD$24.1001|
|Wall St. target price||USD$36.8|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||N/A|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||USD$0|
|Return on assets TTM||0%|
|Return on equity TTM||0%|
|Market capitalisation||USD$1 billion|
TTM: trailing 12 months
There are currently 1.1 million Taysha Gene Therapies shares held short by investors – that's known as Taysha Gene Therapies's "short interest". This figure is 9% down from 1.3 million last month.
There are a few different ways that this level of interest in shorting Taysha Gene Therapies shares can be evaluated.
Taysha Gene Therapies's "short interest ratio" (SIR) is the quantity of Taysha Gene Therapies shares currently shorted divided by the average quantity of Taysha Gene Therapies shares traded daily (recently around 105104.94053065). Taysha Gene Therapies's SIR currently stands at 10.93. In other words for every 100,000 Taysha Gene Therapies shares traded daily on the market, roughly 10930 shares are currently held short.
To gain some more context, you can compare Taysha Gene Therapies's short interest ratio against those of similar companies.
However Taysha Gene Therapies's short interest can also be evaluated against the total number of Taysha Gene Therapies shares, or, against the total number of tradable Taysha Gene Therapies shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Taysha Gene Therapies's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Taysha Gene Therapies shares in existence, roughly 30 shares are currently held short) or 0.0632% of the tradable shares (for every 100,000 tradable Taysha Gene Therapies shares, roughly 63 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Taysha Gene Therapies.
Find out more about how you can short Taysha Gene Therapies stock.
We're not expecting Taysha Gene Therapies to pay a dividend over the next 12 months.
Taysha Gene Therapies, Inc., a gene therapy company, develops adeno-associated virus based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-101 for the treatment of GM2 gangliosidosis; TSHA-118 for the treatment of CLN1 disease; TSHA-102 for the treatment of Rett syndrome; TSHA-103 for the treatment of SLC6A1 haploinsufficiency disorder; and TSHA-104 for the treatment for Surfeit locus 1 deficiency. The company also has strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. Taysha Gene Therapies, Inc. was founded in 2019 and is based in Dallas, Texas.
If you’re looking for a broker comparable to Vanguard, check out these five contenders.
Thinking of switching from TD Ameritrade? Here are 5 apps like TD Ameritrade that offer valuable benefits.
Our picks of the best overwater stays in the Land of Smiles from budget-friendly to luxurious.
This guide will show you step-by-step instructions on how to buy the Reserve Rights (RSR) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the Curve (CRV) token as well as a list of exchanges you can trade it on.
Acorns alternatives offer lower fees and more investment options. Learn more.
Hanna Andersson’s Organic Cotton Long John is comfortable and available in family sizes. Here’s what I thought of the fit, and details on sustainability.
Find in-stock face masks for wildires, smoke and dust, see our top picks and read tips for using respirator smoke masks.
The Chairman of Dubai’s IBC Group has pledged a whopping $4.8 billion into Bitcoin, as Microstrategy purchases another $1 billion of BTC.
This guide will show you step-by-step instructions on how to buy the Maker (MKR) token as well as a list of exchanges you can trade it on.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.